Cell therapy (TCR-T) · Kills target cells, directed at tumor-associated antigen (not yet identified) · developed by Immatics US
IMA201 is an autologous T-cell therapy in which a patient's T lymphocytes are genetically modified with a lentiviral vector to express a T-cell receptor specific for a tumor-associated antigen. After intravenous infusion, the engineered T cells recognize and bind the antigen on cancer cells and mediate a cytotoxic T-lymphocyte response. It is studied in solid tumors, including recurrent and refractory solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03247309 | Phase 1 | Solid Tumor | Completed | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerRecurrent Solid TumorsRefractory Solid TumorsSolid Tumor
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →